Integer Holdings Co. (NYSE:ITGR) Shares Sold by Fuller & Thaler Asset Management Inc.

Fuller & Thaler Asset Management Inc. lessened its stake in Integer Holdings Co. (NYSE:ITGR) by 0.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 977,172 shares of the medical equipment provider’s stock after selling 4,014 shares during the quarter. Fuller & Thaler Asset Management Inc. owned about 2.91% of Integer worth $129,495,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in ITGR. Mather Group LLC. increased its holdings in shares of Integer by 304.3% during the 4th quarter. Mather Group LLC. now owns 190 shares of the medical equipment provider’s stock worth $25,000 after buying an additional 143 shares during the last quarter. Lee Danner & Bass Inc. purchased a new position in Integer in the fourth quarter worth approximately $27,000. R Squared Ltd acquired a new stake in Integer during the fourth quarter worth $44,000. Sterling Capital Management LLC raised its position in Integer by 472.9% in the fourth quarter. Sterling Capital Management LLC now owns 338 shares of the medical equipment provider’s stock valued at $45,000 after purchasing an additional 279 shares during the period. Finally, Versant Capital Management Inc lifted its stake in shares of Integer by 98.4% in the 4th quarter. Versant Capital Management Inc now owns 369 shares of the medical equipment provider’s stock valued at $49,000 after purchasing an additional 183 shares during the last quarter. Hedge funds and other institutional investors own 99.29% of the company’s stock.

Integer Stock Performance

NYSE:ITGR opened at $118.12 on Wednesday. The company has a market cap of $4.12 billion, a price-to-earnings ratio of 35.16, a price-to-earnings-growth ratio of 1.72 and a beta of 1.09. The company has a quick ratio of 2.09, a current ratio of 2.95 and a debt-to-equity ratio of 0.62. Integer Holdings Co. has a 52 week low of $104.93 and a 52 week high of $146.36. The company has a fifty day simple moving average of $120.73 and a two-hundred day simple moving average of $130.42.

Integer (NYSE:ITGR) last issued its quarterly earnings results on Thursday, February 20th. The medical equipment provider reported $1.43 earnings per share for the quarter, missing the consensus estimate of $1.46 by ($0.03). Integer had a return on equity of 11.65% and a net margin of 6.92%. The company had revenue of $449.50 million for the quarter, compared to analysts’ expectations of $446.28 million. As a group, equities analysts anticipate that Integer Holdings Co. will post 6.01 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the stock. Truist Financial reduced their price objective on shares of Integer from $163.00 to $140.00 and set a “buy” rating on the stock in a report on Friday, April 11th. Benchmark boosted their price target on shares of Integer from $140.00 to $150.00 and gave the company a “buy” rating in a research note on Friday, February 21st. Oppenheimer cut shares of Integer from an “outperform” rating to a “market perform” rating in a research report on Friday, February 21st. KeyCorp cut their target price on Integer from $154.00 to $145.00 and set an “overweight” rating on the stock in a research report on Monday. Finally, Raymond James started coverage on Integer in a research report on Friday, March 28th. They set an “outperform” rating and a $145.00 price target for the company. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, Integer has a consensus rating of “Moderate Buy” and an average target price of $145.00.

Integer Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.